Xenon Pharmaceuticals has been awarded the LifeSciences British Columbia Life Sciences Company of the Year Award.
The Burnaby company develops genetics-based drugs. One of its drugs is now used to treat lipoprotein lipase deficiency. It also has a pain medication and a drug to treat anemia in development.
In December 2012, Teva Pharmaceuticals (NYSE:TEVA) announced it would pay Xenon up to $376 million for a worldwide license for a pain drug.
"This is the beginning of a very exciting year for Xenon," said Simon Pimstone, president and CEO of Xenon. "We've worked diligently and deliberately to create strong partnerships with top-tier pharmaceutical companies and to develop a deep and diverse pipeline of products."
